BS_DHA5FMVW
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 87.25361366622865
- age_years
- 8.17
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.533
- E2F_TARGETS+0.502
- MYC_TARGETS_V1+0.463
- ALLOGRAFT_REJECTION+0.419
- INTERFERON_GAMMA_RESPONSE+0.405
- G2M_CHECKPOINT+0.403
- INTERFERON_ALPHA_RESPONSE+0.359
- UNFOLDED_PROTEIN_RESPONSE+0.281
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- IL2_STAT5_SIGNALING+0.218
Top 10 suppressed
- NOTCH_SIGNALING-0.392
- ADIPOGENESIS-0.360
- PANCREAS_BETA_CELLS-0.309
- BILE_ACID_METABOLISM-0.290
- WNT_BETA_CATENIN_SIGNALING-0.266
- HEME_METABOLISM-0.259
- PEROXISOME-0.253
- HEDGEHOG_SIGNALING-0.243
- CHOLESTEROL_HOMEOSTASIS-0.236
- FATTY_ACID_METABOLISM-0.228
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QX12J6W1 | ATRT | — | 0.818 |
| 2 | SRR26320090 | — | — | 0.787 |
| 3 | MDT-AP-0599 | Med | Medulloblastoma | 0.787 |
| 4 | BS_GAGRGSSX | ATRT | — | 0.785 |
| 5 | a45a7511-4aa9-4d04-8f5f-34d12e4d5917 | — | — | 0.785 |
| 6 | TCGA-GV-A40E-01A-12R-A23N-07 | — | — | 0.781 |
| 7 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.769 |
| 8 | MBCProject_4989_T1_RNA | — | C | 0.766 |
| 9 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.758 |
| 10 | SRR29022833 | — | D | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.533 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.502 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.463 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.419 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.405 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.403 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.359 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.281 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.218 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.198 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.156 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.151 | Inavolisib | — uncovered |
| COMPLEMENT | 0.139 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.122 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.121 | Inavolisib | — uncovered |
| COAGULATION | 0.097 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.085 | Inavolisib | — uncovered |
| APOPTOSIS | 0.083 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.082 | Temsirolimus | — uncovered |